Current Report Filing (8-k)
October 02 2014 - 08:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
October 2, 2014
Date of Report (Date of Earliest
Event Reported)
IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
000-31187 |
870299034 |
(State or other jurisdiction of |
(Commission File |
(IRS Employer Identification |
incorporation) |
Number) |
No.) |
6425 Abrams, Ville St- Laurent, Quebec, Canada |
H4S 1X9 |
(Address of principal executive offices) |
(Zip Code) |
Registrant's telephone number, including area code: (514)
331-7440
Check the appropriate box below if the Form 8K fining is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17CFR230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communication pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 5.02. Appointment of Certain Officers.
IntelGenx today announced that its Board of Directors has
unanimously appointed Dr. Horst G. Zerbe to serve as the Companys President and
Chief Executive Officer. Dr. Zerbe has served as interim President and CEO since
July 15, 2014.
Dr. Zerbe (67) has more than 30 years experience in the
pharmaceutical industry. Dr. Zerbe is the Chairman of the Board of Directors,
Founder of IntelGenx, and former President and Chief Executive Officer of the
Company. He retired from the positions of President and Chief Executive Officer
effective December 31, 2013, a position that he held since April 2006. In
addition, Dr. Zerbe served as the President, Chief Executive Officer and
Director of IntelGenx Corp., our Canadian Subsidiary, from 2005 until December
31, 2013. From 1998 to 2005, he served as the President of Smartrix Technologies
Inc. in Montreal; prior thereto, from 1994 to 1998, he was Vice President of
R&D at LTS Lohmann Therapy Systems in West Caldwell, NJ. Dr. Zerbe has
extensive executive level experience, and has been responsible for many
strategic and business initiatives. Dr. Zerbe has been involved in new drug
development and the acquisition and disposition of new drug candidates and other
technology, licensing and distribution matters that are likely to affect our
companys own business efforts. He has published numerous scientific papers in
recognized journals and holds over 30 patents. Dr. Zerbe is married to Ingrid
Zerbe, the Companys Corporate Secretary.
Item 8.01 Other Events.
On October 2, 2014, the Company issued a press release
announcing the appointment of Dr. Horst G. Zerbe as President and Chief
Executive Officer. A copy of the press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
INTELGENX TECHNOLOGIES CORP. |
|
|
Dated: October 2, 2014 |
By: /s/ J. Bernard
Boudreau |
|
J. Bernard Boudreau |
|
Vice Chairman of the Board of Directors
|
Exhibit 99.1
IntelGenx Founder Returns as President and CEO
Saint Laurent, Quebec - October 2, 2014 - Saint Laurent, Quebec - IntelGenx Corp.
(TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that its board of
directors unanimously decided to appoint the companys founder, Dr. Horst G.
Zerbe, as President and Chief Executive Officer. Dr. Zerbe led the company in
the same roles from April 2006 to December 2013 and also has been serving as
interim President and CEO since July 2014.
As both a pioneer and expert in drug
delivery systems, there is no better decision we could have made than to have
Dr. Zerbe return to the helm of IntelGenx, said J. Bernard Boudreau, IntelGenx
Vice-Chairman of the Board. We are confident in his ability to move the company
forward and create shareholder value.
Dr. Zerbe has more than 30 years
experience in Pharmaceutical R&D, technology management, business
development and corporate management.
During my entire professional carrier, and
particularly since founding IntelGenx in 2003, it has been my goal to develop
novel drug delivery systems that are of significant benefit to patients, said
Zerbe. Although I have remained an integral part of company strategy and
operations since its inception, I now look forward to once again leading
IntelGenx as we bring our proprietary technologies into new markets and move the
company towards revenue growth and profitability.
Prior to founding IntelGenx, Dr. Zerbe
served as the president of Smartrix Technologies Inc. in Montreal, and as Vice
President of R&D at LTS Lohmann Therapy Systems in West Caldwell, NJ. Dr.
Zerbe holds more than 40 patents in drug delivery related fields and has
published numerous scientific papers in recognized journals.
About IntelGenx:
IntelGenx is a drug delivery company
focused on the development of oral controlled-release products as well as novel
rapidly disintegrating delivery systems. IntelGenx uses its unique multiple
layer delivery system to provide zero-order release of active drugs in the
gastrointestinal tract. IntelGenx has also developed novel delivery technologies
for the rapid delivery of pharmaceutically active substances in the oral cavity
based on its experience with rapidly disintegrating films. IntelGenx'
development pipeline includes products for the treatment of indications such as
severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS
indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal
health products. More information is available about the company at
www.intelgenx.com.
Investor Contact: |
Company Contact:
|
|
|
COCKRELL GROUP |
Paul A. Simmons
|
T: 877.889.1972 |
Chief Financial Officer
|
investorrelations@thecockrellgroup.com |
IntelGenx Technologies
Corp. |
cockrellgroup.com |
T: +1 514-331-7440
|
|
F: +1 514-331-0436
|
|
intelgenx.com |
IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From Feb 2024 to Mar 2024
IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From Mar 2023 to Mar 2024